RYAM News & Events

Mill Pond Capital, which owns approximately 3% of the outstanding common shares of Rayonier Advanced Materials, sent a letter to the company's Board of Directors urging the Board to conduct a full sale of RYAM. In the letter, Daniel Farb, Managing Member of Mill Pond Capital, stated in part, "I first became a shareholder of Rayonier Advanced Materials in 2019 and currently own approximately 3% of the company's outstanding common shares, making me one of the company's larger shareholders. I have a successful history of investing in commodity-related businesses and, like each of you on RYAM's Board of Directors, have served on public company boards in the commodity space. I am writing today following a private letter I sent on May 8, 2026, and a subsequent call with Chair Dill, in which I stated my belief that a full sale of RYAM is the best path forward for the company. This limited engagement from Chair Dill produced only the assurance that the Board is 'working to do what is best for shareholders.' After seven years of receiving that assurance - and being unable to present my views to the broader Board - I am no longer content to wait for a different result."

Reports Q1 revenue $319M, consensus $302.63M. "Our first quarter performance was consistent with the trajectory we outlined in March, with early progress on pricing and mix in Cellulose Specialties and positive adjusted free cash flow despite a low earnings base," said Marcus Moeltner, Office of the CEO, Chief Financial Officer and Senior Vice President of Finance.

Rayonier Advanced Materials announced that the Company is engaged in a formal process to explore strategic alternatives to maximize shareholder value. In connection with the strategic alternatives review, the Company has engaged Morgan Stanley & Co. as its financial advisor and Wachtell, Lipton, Rosen & Katz as its legal counsel. The strategic review will consider a range of potential strategic, business and financial alternatives, which may include, among other things, a sale of all or part of the Company, a strategic investment, a merger or other business combination, or other strategic or financial alternatives, as well as continuing to execute on the Company's standalone strategic plan. The Board remains confident that its approach-which is grounded in disciplined governance, transparency, and a commitment to sustainable value creation-is in the best interests of stockholders, customers, employees and all stakeholders. The Board has not set a timetable for completion of the strategic review and does not intend to provide updates unless and until it is determined that disclosure is appropriate or required by law. There can be no assurance that the strategic alternatives review process will result in any transaction or other strategic change.

The Company announced that its Board of Directors has established an interim Office of the CEO following the resignation of President and CEO Scott M. Sutton, effective immediately. The OFC will comprise current executives to guide the company through this transition period, including Marcus Moeltner, CFO and SVP of Finance; Michael Osborne, VP of Manufacturing Operations; Christian Ribeyrolle, SVP of Biomaterials; and R. Colby Slaughter, SVP, General Counsel and Corporate Secretary.